Early effect of amifostine in treating aged patients with idiopathic thrombocytopenia purpura.
- Author:
Hui FAN
1
;
Hong-Li ZHU
;
Shan-Qian YAO
;
Xue-Chun LU
;
Xiao-Meng ZHUANG
;
Yang YANG
Author Information
1. Department of Geriatric Hematology, General Hospital of PLA, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Aged, 80 and over;
Amifostine;
therapeutic use;
Drug Administration Schedule;
Humans;
Male;
Platelet Count;
Purpura, Thrombocytopenic, Idiopathic;
drug therapy;
Treatment Outcome
- From:
Journal of Experimental Hematology
2006;14(2):301-303
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to explore the effect of amifostine in treating aged patients with idiopathic thrombocytopenic purpura (ITP). Three aged ITP patients (one aged 88, one aged 75, another aged 65) were treated with amifostine over a period of 4 weeks for each. The results showed that the early positive responses were observed in all 3 aged patients after treatment with amifostine 5 x 400 mg per week for 4 weeks, the recovery of platelet counts to normal level were found in 2 cases after 1 week and in 1 case after 2 weeks. Following 4 months after stop of treatment with amifostine, the normal platelet counts still remains in all patients, no more blood transfusions, hormonal preparation and gamma-globulin were given. Amifostine has never been reported elewhere as to treat of aged ITP. In conclusion, amifostine has a good early therapeutic effect on aged ITP patients, but its clinical outcome of long-term still needs further evaluation.
